Spectrum Pharmaceuticals, Inc. announced that it has entered in equity purchase agreement for the issuance of 12,500,000 common shares at a price of $1.6 per common share for a total gross proceeds of $20,000,000 on January 4, 2022. The transaction will include participation from returning investor Hanmi Pharm. Co., Ltd. The transaction is expected to close on or around January 6, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
3,04,500 KRW | +1.84% |
|
+0.83% | -13.62% |
10/07 | Hanmi Pharm Chair to Resign from Management | MT |
16/05 | Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-13.62% | 2.8B | |
+26.58% | 45.33B | |
+38.49% | 25.36B | |
+27.53% | 16.7B | |
+20.89% | 14.59B | |
+72.03% | 14.26B | |
-0.05% | 6.79B | |
-10.35% | 6.67B | |
+13.07% | 5.62B | |
-8.87% | 5.73B |
- Stock Market
- Equities
- A128940 Stock
- News Hanmi Pharm. Co., Ltd.
- Spectrum Pharmaceuticals, Inc. announced that it expects to receive $20 million in funding from Hanmi Pharm. Co., Ltd.